Literature DB >> 8558516

Investigation of (Oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines.

J Alexander1, D S Bindra, J D Glass, M A Holahan, M L Renyer, G S Rork, G R Sitko, M T Stranieri, R F Stupienski, H Veerapanane, J J Cook.   

Abstract

The preparation of (oxodioxolenyl)methyl carbamates and their evaluation as novel nonchiral prodrug moieties for chiral primary and secondary amino functional drugs are described. 4-(Carbamoylmethyl)-2-oxo-1,3-dioxolene derivatives of 3,4-dimethoxyphenethylamine with 5-methyl, 5-phenyl, and 5-anisyl substitution (5a, 5b, and 5c) on the dioxolenone ring were prepared as model amine prodrugs by a one step process involving displacement of p-nitrophenol from appropriately substituted ring opening of these carbamates led to a cascade reaction resulting in the rapid and quantitative regeneration of the parent amine drug. Aryl substitution did not significantly alter the hydrolysis rates of these dioxolenone carbamates in buffers at pH 1 and 7.4 or in rat plasma, although the hydrolysis rates of 5-phenyl- (1b) and 5-anisyl- 4-methyl-1,3-dioxol-4-en-2-one (1c) in pH 7.4 phosphate buffer were 2-3 fold faster than that of the 5-methyl-substituted analog (1a). Application of this prodrug strategy to the chiral fibrinogen receptor antagonist L-734,217 resulted in a prodrug that gave quantitative reconversion in rat and dog plasma in vitro and oral bioavailability of 23 +/- 6% in dogs for the parent drug.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558516     DOI: 10.1021/jm9506175

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Stability of alkoxycarbonylamidine prodrugs.

Authors:  Z Shahrokh; E Lee; A G Olivero; R A Matamoros; K D Robarge; A Lee; K J Weise; B K Blackburn; M F Powell
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

3.  Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).

Authors:  Pooja V Hegde; Michael D Howe; Matthew D Zimmerman; Helena I M Boshoff; Sachin Sharma; Brianna Remache; Ziyi Jia; Yan Pan; Anthony D Baughn; Veronique Dartois; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2022-02-19       Impact factor: 6.514

4.  Prodrugs of cephalosporin RWJ-333441 (MC-04,546) with improved aqueous solubility.

Authors:  Scott J Hecker; Trevor Calkins; Mary E Price; Keith Huie; Sharon Chen; Tomasz W Glinka; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Lars Nyman; Brigitte Roos; Michael Schleimer; Jill Sauer; Norman Nashed; Thomas Brown; Anthony Man; Erhard Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 6.  Prodrugs for amines.

Authors:  Ana L Simplício; John M Clancy; John F Gilmer
Journal:  Molecules       Date:  2008-03-03       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.